| Ytd | 46.77% | |
| 1y | 156.98% |
| Open | 114.29 | Prev Close | 114.67 | Low | 112.28 | High | 116.75 | Mkt Cap | 9.39B |
| Vol | 862.39K | Avg Vol | 762.83K | EPS | -3.57 | P/E | N/A | Forward P/E | -26.28 |
| Beta | 2.03 | Short Ratio | 17.34 | Inst. Own | 112.54% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 86.26 | 200-d Avg | 76.09 | 1yr Est | 123.76 |
KYMR News
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data t
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and
Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy a
It completed the enrollment phase of a Phase 2b study of its leading drug candidate. This medication
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-st
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and
Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The l
Kymera Therapeutics Inc. (NASDAQ:KYMR) shares are trading higher by more than 21% on Thursday as the
Kymera Therapeutics shares surged after completing KT-621 Phase 2b enrollment early, accelerating da
BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintain
U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, whil
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re
BROADEN2 enrollment completed nearly six months ahead of anticipated timelinesKT-621 Phase 3 trials
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
"The consistency we've demonstrated across KT-621 Phase 1 studies, from robust STAT6 degrada
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million miles
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and cli